—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Zealand Pharma A/S (ZEAL.CO) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for ZEAL.CO, from the same nightly bakes the boards use. Research diary readings, not advice.

Versus its index HALO Growth 100 — the name, its sleeve and the index over day, week and month

Versus its index

The name against its Closelooknet index and its own sleeve — equal-weight, nightly closes.

HALO Growth 100 · as of 2026-09-25

DayWeekMonth3 months
ZEAL.CO−1.2%−3.3%−14.0%−5.8%
Longevity & Healthspan−0.3%+4.5%+0.5%—
HALO Growth 1000.0%+0.2%−7.6%—

Against the index: 3.5 pts behind on the week, 6.4 pts behind on the month; against its Longevity & Healthspan sleeve 14.5 pts behind on the month.

Returns from the index workers’ nightly closes; equal-weight sleeves. A relative reading from the research diary, not advice.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 62/100 · S&P 500 fund at 67, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-25
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +8.4% over 20 sessions. Factor regime → 2026-09-25
  • Sector × region Health care in Europe: +0.1% week · −3.6% month · −4.6% quarter · −1.5% yearThe Sector Engine cell this name lives in, from EXV4.XETRA; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-27
  • Sovereign pressure Index 0.61 · up 0.29 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-25
Who it is priced against HALO Growth 100 · Longevity & Healthspan · 8 names with week and year-to-date

Peer group

HALO Growth 100 · Longevity & Healthspan

GLP-1 leaders, gene-editing platforms, diagnostics-at-scale, biopharma compounders. Demographics writes the demand curve.

Compared against ZEAL.CO on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Zealand Pharma A/S

ZEAL.CO in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Zealand Pharma develops peptide-based medicines for gastrointestinal and metabolic conditions, operating from Denmark with a further base in the United States. Its marketed products include an injector treatment for severe low blood sugar and a dual-hormone system pairing insulin with a glucagon-like peptide for an artificial pancreas approach. A further candidate, a long-acting peptide for short bowel syndrome, is in late-stage trials. The company is based in Søborg, Denmark.
Where it sits in the stack
Zealand Pharma carries no seat in Rubin, our AI build-out index, and sits instead in the diary's broader growth universe. It belongs to the Longevity & Healthspan sleeve, the grouping we use for biopharma names whose demand follows demographic trends rather than a build-out cycle.
Who it is priced against
The diary groups it with GLP-1 leaders, gene-editing platforms, diagnostics-at-scale names and biopharma compounders inside the Longevity & Healthspan sleeve, alongside Eli Lilly, Novo Nordisk, Regeneron, Vertex, Illumina, Amgen, Natera and Gerresheimer.
Why Closelooknet tracks it
It holds a seat in our HALO Growth 100 index and carries a Closelooknet score, with the balance-sheet module reading strongest and momentum weakest. The diary has not yet quoted it in any edition.
What the diary watches
How the late-stage trial for the short bowel syndrome candidate progresses, and whether momentum recovers from its current weak reading as the pipeline advances.

Zealand Pharma A/S (ZEAL.CO) trades on the CO exchange in Denmark, classified under Healthcare. Constituent of HALO Growth 100.

The Closelooknet company score reads 59/100 composite (momentum 20, quality 71, valuation 75) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Dividends and capital return no distribution in twelve months · buybacks 407 m DKK in FY2025

Dividends and capital return

What ZEAL.CO pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Buybacks, FY2025 407 m DKK 2.1% of today's market value
  • Share count +7.7% in FY2025 116 m DKK of stock-based compensation in the year
  • Capital returned 407 m DKK · 6% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-09-26

Quick answers

What is Zealand Pharma A/S (ZEAL.CO)?

Zealand Pharma A/S trades as ZEAL.CO on the CO exchange (Denmark) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-09-26.

Is ZEAL.CO in a Closelooknet index?

Yes — Zealand Pharma A/S is a constituent of HALO Growth 100, as of 2026-09-26.

What is Zealand Pharma A/S's Closelooknet composite score?

59 out of 100, with momentum 20, quality 71 and valuation 75 sub-scores, as of 2026-09-26. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does ZEAL.CO trade against its moving averages?

Resizing — 50.4% off its high: 50.4% below its 52-week high, under its 200-day — a deeper resizing of the trend, not a shallow dip. As of 2026-09-24 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How is ZEAL.CO doing against its Closelooknet index?

Over the past month Zealand Pharma A/S is −14.0% against −7.6% for the HALO Growth 100 — 6.4 points behind its index, as of 2026-09-25. Its Longevity & Healthspan sleeve is +0.5% over the same month. The “Versus its index” table on this page carries the day, the week and the month for the name, its sleeve and the index.

What does Zealand Pharma A/S do?

Zealand Pharma develops peptide-based medicines for gastrointestinal and metabolic conditions, operating from Denmark with a further base in the United States. Its marketed products include an injector treatment for severe low blood sugar and a dual-hormone system pairing insulin with a glucagon-like peptide for an artificial pancreas approach. A further candidate, a long-acting peptide for short bowel syndrome, is in late-stage trials. The diary groups it with GLP-1 leaders, gene-editing platforms, diagnostics-at-scale names and biopharma compounders inside the Longevity & Healthspan sleeve, alongside Eli Lilly, Novo Nordisk, Regeneron, Vertex, Illumina, Amgen, Natera and Gerresheimer.

Where does Zealand Pharma A/S sit in the AI build-out?

Zealand Pharma carries no seat in Rubin, our AI build-out index, and sits instead in the diary's broader growth universe. It belongs to the Longevity & Healthspan sleeve, the grouping we use for biopharma names whose demand follows demographic trends rather than a build-out cycle. It holds a seat in our HALO Growth 100 index and carries a Closelooknet score, with the balance-sheet module reading strongest and momentum weakest. The diary has not yet quoted it in any edition.

Does Zealand Pharma A/S pay a dividend?

No cash distribution shows in Zealand Pharma A/S’s price series over the last three years. In fiscal 2025 the company bought back 407 m DKK of its own shares, 6% of that year’s free cash flow. The share count rose 7.7% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for ZEAL.CO, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

same Closelooknet index seat first, then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.